Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 14/20 | 0.62 |
| ▸ | PARP1 | P09874 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | NCF1 | P14598 | 1/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.51 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.51 |
| ▸ | MC4R | P32245 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29817837 | 0.95 | PARP1 (0.59) | CHKAPARP1CHEK1PARP2PARP3 | |
| SCHEMBL17465322 | 0.89 | CHKA (0.64) | CHKACA2NCF1PRMT6MC4R | |
| SCHEMBL29537476 | 0.81 | MEN1 (0.50) | PARP1 | |
| SCHEMBL17729936 | 0.81 | BCAT2 (0.59) | PARP1CHEK1PARP2PARP3 | |
| SCHEMBL31717616 | 0.80 | PARP1 (0.59) | PARP1PARP2PARP3 | |
| Hydrochloric Acid SCHEMBL31717432 | 0.79 | PARP1 (0.58) | PARP1PARP2PARP3 | |
| SCHEMBL17465323 | 0.78 | CHKA (1.00) | CHKACA2NCF1PRMT6MC4R | |
| SCHEMBL16121577 | 0.77 | CHKA (1.00) | CHKACA2NCF1PRMT6MC4R | |
| SCHEMBL16121659 | 0.77 | CHKA (0.67) | CHKACA2NCF1PRMT6MC4R | |
| SCHEMBL28684963 | 0.76 | PARP1 (0.58) | CHKAPARP1CHEK1PARP2PARP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834521-B2 | Choline kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834521-B2 | Choline kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834521-B2 | Choline kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160024024-A1 | Novel Choline Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160024024-A1 | Novel Choline Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160024024-A1 | Novel Choline Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| WO-2014151761-A1 | NOVEL CHOLINE KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024024-A1 | Novel Choline Kinase Inhibitors | CHKA, CHKB, CEPT1 | CHKA 1/4885PARP1 3205/4885CA2 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.